-
1.发明公开公开(公告)号：US20240197871A1
公开(公告)日：2024-06-20
申请号：US18284800
申请日：2022-03-29
Applicant: Juno Therapeutics, Inc.
Inventor： Nikolaus Sebastian TREDE , Tim PULHAM , Fan WU , Michael POURDEHNAD , Joseph Andrew DESTEFANO , Maria Soraya CARRANCIO ANTON , Tonia Jane BUCHHOLZ , Michael PORTS , Jim QIN , Ronald DUBOWY , Nicolas BRAND
IPC: A61K39/00 , A61K31/5377 , A61K31/675 , A61K31/7076 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/28
CPC classification number: A61K39/4611 , A61K31/5377 , A61K31/675 , A61K31/7076 , A61K39/4631 , A61K39/464412 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/2803 , A61K2239/26 , A61K2239/38 , A61K2239/39 , C07K2319/02 , C07K2319/03
Abstract: Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.
-
公开(公告)号：US20240115704A1
公开(公告)日：2024-04-11
申请号：US18285646
申请日：2022-04-06
Applicant: Artiva Biotherapeutics, Inc. , GC Cell Corporation
Inventor： Peter FLYNN , Jason B. LITTEN , Thomas James FARRELL , John Kin Chuan LIM , Mili MANDAL , Srinivas Sai SOMANCHI , Yusun KIM , Sungyoo CHO , Yu Kyeong HWANG
IPC: A61K39/00 , A61K39/395 , C12N5/0783
CPC classification number: A61K39/4613 , A61K39/39558 , A61K39/464499 , C12N5/0646 , A61K2239/26 , A61K2239/38 , A61K2239/39 , A61K2239/48 , C12N2502/1114
Abstract: Provided herein are, among other things, methods for treating a patient suffering from a CD38+ cancer.
-
公开(公告)号：US20240336893A1
公开(公告)日：2024-10-10
申请号：US18291999
申请日：2022-07-28
Inventor： James MULÉ , Daniel ABATE-DAGA
IPC: C12N5/0783 , A61K39/00 , C07K16/28 , C12Q1/6886
CPC classification number: C12N5/0636 , A61K39/4611 , A61K39/464499 , C07K16/2878 , C12Q1/6886 , A61K2239/39 , C07K2317/75 , C12N2501/52 , C12Q2600/158
Abstract: Disclosed herein is a method for predicting the responsiveness of a subject to CD40 agonist therapy, such as agonist anti-CD40 therapy, that involves assaying a tumor sample from the subject for a 12 Chemokine gene signature demonstrating that the tumor comprises tertiary lymphoid structures containing B cells. Therefore, also disclosed herein is a method of treating tumors, such as solid tumors, in a subject that involves administering to the subject an effective amount of a composition comprising assaying a tumor sample from the subject for a 12 Chemokine gene signature demonstrating that the tumor comprises tertiary lymphoid structures (TLS) containing B cells, and treating the subject with CD40 agonist therapy, such an agonist anti-CD40 antibody.
-
公开(公告)号：US20240325539A1
公开(公告)日：2024-10-03
申请号：US18249769
申请日：2021-10-20
Applicant: The Chancellor, Masters and Scholars of the University of Oxford , Imperial College Innovations Limited
Inventor： Xin Lu , Xiao-Ning Xu , Nadia Khan , Stefanie Zentelis
IPC: A61K39/00 , A61K31/136 , A61K31/4406 , A61K31/454 , A61K31/473 , A61K31/496 , A61K31/506 , A61K31/704 , A61K31/7048 , C07K14/725 , C07K16/08
CPC classification number: A61K39/464838 , A61K31/136 , A61K31/4406 , A61K31/454 , A61K31/473 , A61K31/496 , A61K31/506 , A61K31/704 , A61K31/7048 , A61K39/4611 , A61K39/4632 , C07K14/7051 , C07K16/085 , A61K2239/39 , A61K2239/51
Abstract: This disclosure describes a novel “kick and kill” strategy as an effective cancer therapy for treating virus-associated cancers. In particular, this disclosure provides a method of reactivating a latent Epstein-Barr virus (EBV) in a cell infected with the EBV. Also provided are a method of eliciting or enhancing an immune response against an EBV-positive cancer cell in a subject infected with the EBV and a method of treating a subject having cancer associated with EBV infection.
-
公开(公告)号：US20240287202A1
公开(公告)日：2024-08-29
申请号：US18568387
申请日：2021-06-08
Applicant: XYPHOS BIOSCIENCES INC.
Inventor： Kaman Kim , Kyle Landgraf
IPC: C07K16/28 , A61K39/00 , A61P35/00 , C07K14/705
CPC classification number: C07K16/2887 , A61K39/4611 , A61K39/4631 , A61K39/464424 , A61P35/00 , C07K14/7056 , A61K2039/505 , A61K2239/15 , A61K2239/39 , C07K2317/734 , C07K2317/92 , C07K2319/33
Abstract: The disclosure provides an antibody fusion protein comprising (i) heavy chains comprising variable region sequences comprising the amino acid sequence of SEQ ID NO: 1 and (ii) light chains comprising variable region sequences comprising the amino acid sequence of SEQ ID NO: 8, wherein the light chains are fused at the C-terminus to an A1-A2 domain comprising the amino acid sequence of SEQ ID NO: 11. Nucleic acids encoding all or part of the antibody fusion protein are provided, as well as methods of using the antibody fusion protein in the treatment of, e.g., CD20-positive cancers.
-
6.发明公开
公开(公告)号：US20240166706A1
公开(公告)日：2024-05-23
申请号：US18516561
申请日：2023-11-21
Applicant: Wisconsin Alumni Research Foundation
Inventor： Jacques Galipeau , Rahul Das
IPC: C07K14/54 , A61K39/00 , A61P35/00 , C07K14/545 , C12N5/0783
CPC classification number: C07K14/5412 , A61K39/4611 , A61K39/4635 , A61K39/464499 , A61P35/00 , C07K14/545 , C12N5/0638 , A61K38/00 , A61K2239/26 , A61K2239/39 , A61K2239/59 , C07K2319/00 , C12N2510/00
Abstract: The present invention provides novel fusion proteins comprising two cytokines: interleukin-6 (IL-6) and interleukin-1 beta (IL-1β). Methods of using the fusion proteins to activate target cells or treat a disease are also provided.
-
公开(公告)号：US20240299540A1
公开(公告)日：2024-09-12
申请号：US18262843
申请日：2022-02-07
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Frederick G. Vogt , Cecile Chartier-Courtaud
IPC: A61K39/00 , A61K39/395 , A61N1/32 , C12N5/0783
CPC classification number: A61K39/4611 , A61K39/3955 , A61K39/464499 , A61N1/327 , C12N5/0636 , A61K2239/38 , A61K2239/39 , C12N2501/2302 , C12N2502/30
Abstract: The present invention provides methods for expanding TILs and producing therapeutic populations of TILs. According to exemplary embodiments, at least a portion of the therapeutic population of TILs are gene-edited to enhance their therapeutic effect. According to further embodiments, methods for gene-editing TILs include intratumoral delivery of expression vectors for immune checkpoint inhibitors using an electroporation system prior to harvesting the tumor for TIL production. According to yet further embodiments, an adjuvant therapy for cancer includes delivery of expression vectors for immune checkpoint inhibitors before, after or before and after infusion of TILs for treating cancer.
-
8.发明公开
公开(公告)号：US20240299539A1
公开(公告)日：2024-09-12
申请号：US18256798
申请日：2021-12-16
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Maria FARDIS , Friedrich Graf Finck FINCKENSTEIN , Zelanna GOLDBERG
IPC: A61K39/00 , A61K39/395 , A61P35/00 , C12N5/0783
CPC classification number: A61K39/4611 , A61K39/395 , A61K39/464499 , A61P35/00 , C12N5/0636 , A61K2039/507 , A61K2239/39 , C12N2501/2302 , C12N2501/2315 , C12N2501/2321 , C12N2502/00
Abstract: The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of cancer with TILs in combination with CT-LA-4 and PD-1 inhibitors and/or PD-L1 inhibitors as described herein.
-
公开(公告)号：US20240115703A1
公开(公告)日：2024-04-11
申请号：US18482752
申请日：2023-10-06
Applicant: CRISPR Therapeutics AG
Inventor： Ziliang LI , Annie Yang WEAVER , Sarah COHEN , Ewelina MORAWA
CPC classification number: A61K39/4611 , A61K39/4631 , A61K39/464412 , A61P35/00 , A61P35/02 , A61K2239/38 , A61K2239/39 , A61K2239/48
Abstract: Methods for treating B-cell malignancies such as relapsed and/or refractory B-cell malignancies with a population of genetically engineered T cells expressing a chimeric antigen receptor (CAR) targeting CD19 and having multiple genetic edits, including a disrupted TRAC gene, a disrupted β2M gene, a disrupted Regnase 1 gene, and/or a disrupted TGFBRII gene.
-
公开(公告)号：US20240058458A1
公开(公告)日：2024-02-22
申请号：US17905748
申请日：2021-03-05
Applicant: Purdue Research Foundation
Inventor： Philip S. LOW , John Victor NAPOLEON , Qian LUO
CPC classification number: A61K47/555 , A61K39/4611 , A61K39/4631 , A61K39/4646 , A61K47/551 , A61K47/558 , A61K47/60 , A61K2239/39
Abstract: Compounds, compositions and methods for reducing off-target toxicity of T cells expressing a chimeric antigen receptor (CAR-T cells) and/or providing enhanced control of CAR-T cell activation, and methods of treating a subject and/or modifying CAR-T cell activity in a subject with cancer.
